Cost-Effectiveness of Thrombolysis within 4.5 Hours of Acute Ischemic Stroke in China

Yuesong Pan, Qidong Chen, Xingquan Zhao, Xiaoling Liao, Chunjuan Wang, Waniang Du, Gaifen Liu, Liping Liu, Chunjue Wang, Yilong Wang, Yongjun Wang, for the TIMS-CHINA investigators

Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Abstract

Background: Previous economic studies conducted in developed countries showed intravenous tissue-type plasminogen activator (tPA) is cost-effective for acute ischemic stroke. The present study aimed to determine the cost-effectiveness of tPA treatment in China, the largest developing country.

Methods: A combination of decision tree and Markov model was developed to determine the cost-effectiveness of tPA treatment versus non-tPA treatment within 4.5 hours after stroke onset. Outcomes and costs data were derived from the database of Thrombolysis Implementation and Monitor of acute ischemic Stroke in China (TIMS-China) study. Efficacy data were derived from a pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Costs and quality-adjusted life-years (QALYs) were compared in both short term (2 years) and long term (30 years). One-way and probabilistic sensitivity analyses were performed to test the robustness of the results.

Results: Comparing to non-tPA treatment, tPA treatment within 4.5 hours led to a short-term gain of 0.101 QALYs at an additional cost of CNY 9,520 (US$ 1,460), yielding an incremental cost-effectiveness ratio (ICER) of CNY 94,300 (US$ 14,500) per QALY gained in 2 years; and to a long-term gain of 0.422 QALYs at an additional cost of CNY 6,530 (US$ 1,000), yielding an ICER of CNY 15,500 (US$ 2,380) per QALY gained in 30 years. Probabilistic sensitivity analysis showed that tPA treatment is cost-effective in 98.7% of the simulations at a willingness-to-pay threshold of CNY 105,000 (US$ 16,200) per QALY.

Conclusions: Intravenous tPA treatment within 4.5 hours is highly cost-effective for acute ischemic strokes in China.

Introduction

Stroke accounts for 301 million disability-adjusted life-years, making it the first leading cause of death and imposing significant disease and economic burden in China [1]. Randomized controlled trials and large observational studies have demonstrated the effectiveness with acceptable safety of intravenous recombinant tissue-type plasminogen activator (tPA) for patients within 4.5 hours after onset of acute ischemic stroke [2–6].

Economic studies conducted in North America, Europe and Australia showed tPA given within 4.5 hours is cost-effective or even cost-saving in the long term [7–15]. However, all of these studies were conducted in developed countries; the findings from these countries may not be relevant in developing countries due to their differences in demographics, healthcare systems and payment coverage. Compared with developed countries, the low- and middle-income countries suffer higher mortality burden of stroke [16], and have lower percentage of patients with ischemic stroke treated with tPA [17]. On the other hand, most developed countries, such as United States, implement prospective payment system based on diagnosis related groups [18,19]. While in China, the payments are based on each clinical service. Particularly, the drug costs account for a large part of total costs for Chinese stroke patients. They pay CNY 8,197 (US$ 1,261) just for 70 mg tPA alone [20]. Is the expensive tPA still cost-effective and should it be widely generalized in developing countries like China? Economic analysis of tPA in developing countries is urgent.

Little is known about verifying the cost-effectiveness of tPA treatment in China. We sought to determine the cost-effectiveness of tPA within 4.5 hours after onset of acute ischemic stroke, using the data from the Thrombolysis Implementation and Monitor of acute ischemic Stroke in China (TIMS-China), which is a nationwide prospective registry of thrombolytic therapy with intravenous tPA in patients with acute ischemic stroke between May 2007 and April 2012. TIMS-China has recruited 1,440 consecutive tPA treated patients from 67 centers [21].
Methods

Model Overview

We adhered to the recommendations of the Panel on Cost-effectiveness in Health and Medicine [22], including (1) components belonging in the numerator and denominator of a cost-effectiveness (C/E) ratio; (2) measuring terms in the numerator of a C/E ratio; (3) valuing health consequences in the denominator of a C/E ratio; (4) estimating effectiveness of interventions; (5) incorporating time preference and discounting; and (6) handling uncertainty. A combination of decision tree and Markov model (Figure 1) was developed to simulate the long-term (30 years) cost-effectiveness of tPA treatment versus absence of tPA treatment within 4.5 hours after the onset of stroke. Our study was based on data from 1128 patients with acute ischemic stroke who received intravenous tPA within 4.5 hours in TIMS-CHINA [21]. The base case of model was a cohort of 100,000 patients (39% female), with mean age of 63 years old, arriving at hospital within 4.5 hours after onset of stroke, whose clinical and demographic characteristics are same as patients enrolled in TIMS-CHINA study (Table 1). Total costs and quality-adjusted life-years (QALYs) gained with each alternative were estimated for each health state (Table 1). Total costs and QALYs were discounted by 3% per year [12].

Input Parameters

The baselines of patients and their outcomes in the three time windows (0–1.5, 1.5–3, 3–4.5 hours after the onset of stroke) of the tPA group, were obtained from the observed data directly drawn from the TIMS-CHINA study database (Table 2). Odds ratios of the favorable functional outcome (modified Rankin Scale (mRS) 0–1), death and symptomatic intracerebral hemorrhage (sICH) in each time window were derived from a pooled analysis of the European Cooperative Acute Stroke Study Trial (ECASS), the Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke Trial (ATLANTIS), the National Institute of Neurological Disorders and Stroke (NINDS), and the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) [23]. Odds ratio of sICH within 0–1.5 hours were assumed to be the same as that of within 1.5–3 hours. Favorable functional outcome, death and sICH rates in the non-tPA treatment group were obtained from the observed data of the tPA group and the odds ratios of previous study [23]. The proportional distribution of patients remaining in categories of mRS 2–3 and mRS 4–5 at 90 days in the control group was assumed to be the same as that in tPA group.

Recurrence rates of stroke and mortality rates of recurrent strokes in years after the first 90 days were estimated from the China National Stroke Registry (CNSR, a nationwide registry for patients with acute cerebrovascular events in China between September 2007 and August 2008, recruiting 21,902 consecutive patients from 132 hospitals in China) [24]. We further assumed an increase in stroke recurrence rates by 1.019-fold per life year, according to the relative risk estimated from patients of ischemic stroke in CNSR.

Age specific non-stroke mortality rates were derived from the most recent published census of China and adjusted by the causes of death of 2010 reported in the China Health Statistics Yearbook 2012 [25,26]. Disability status were assumed to affect survival rate, therefore the final age specific non-stroke death rates in the model were adjusted according to the mRS-specific death hazard ratios [7,27]. Patients remaining alive after stroke recurrence were assumed to be reallocated equally among categories of equal and greater disability [12]. For example, patients with minor or moderate disability who had a recurrent stroke and survived were allocated equally among minor or moderate disability category and severe disability category.

Costs

The total costs including both out-of-pocket costs and reimbursements, were converted to 2011 Chinese Yuan Renminbi (CNY) using the medical care component of consumer price index [26]. The average cost of single hospitalization after stroke was obtained from CNSR and the China Health Statistics Yearbook 2012 [26]. Annual post-hospitalization costs (such as inpatient and outpatient rehabilitation, ambulatory care and second prevention costs) were also obtained from CNSR. We estimated the additional costs of tPA treatment and occurrence of sICH after thrombolysis using the data from CNSR and TIMS-CHINA. Indirect economic costs such as lost work productivity were not included in this study. All costs and utilities were discounted by 3% per year [12].

Table 1. Clinical and Demographic Characteristics of Patients Treated with Tissue Plasminogen Activator within 4.5 Hours in TIMS-CHINA Study (N = 1128).

| Characteristic                  | Value          |
|--------------------------------|----------------|
| Age (year), mean (SD)          | 63.48(11.34)   |
| Female, n(%)                   | 440(39.01)     |
| Preadmission modified Rankin Score 0–1, n(%) | 1081(95.83)   |
| NIHSS at admission, median(Q1–Q3) | 117(–16)      |
| Hypertension, n(%)             | 667(59.13)     |
| Diabetes mellitus, n(%)        | 196(17.38)     |
| Dyslipidemia, n(%)             | 73(6.47)       |
| Atrial fibrillation, n(%)      | 208(18.44)     |
| Current smoking, n(%)          | 387(34.31)     |
| History of stroke, n(%)        | 208(18.44)     |

TIMS-CHINA, Thrombolysis Implementation and Monitor of acute ischemic Stroke in China. 

doi:10.1371/journal.pone.0110525.t001
Patients could undergo transitions between four disability states according to functional outcome based on mRS: no disability (mRS 0–1), minor or moderate disability (mRS 2–3), severe disability (mRS 4–5) and dead (mRS 6) [28]. At the end of each cycle, patients could remain in their current health state, transit to a lower level health state due to recurrent stroke, or die due to a recurrent stroke or a non-stroke cause (see Figure 1).

**Figure 1. Markov state-transition model.** All modeled patients started at 63 years old with an acute ischemic stroke receiving either intravenous tissue-type plasminogen activator (tPA) or no tPA treatment within 4.5 hours after the onset of stroke, and transition between health states was tracked until death or the 30-year time horizon is reached. Patients remaining alive after recurrent stroke may transit to category of equal or greater disability. Only transition from minor or moderate disability category was illustrated in the figure. M = Markov node; sICH = symptomatic intracerebral hemorrhage.

doi:10.1371/journal.pone.0110525.g001

**Health States**

Patients could undergo transitions between four disability states according to functional outcome based on mRS: no disability (mRS 0–1), minor or moderate disability (mRS 2–3), severe disability (mRS 4–5) and dead (mRS 6) [28]. At the end of each cycle, patients could remain in their current health state, transit to a lower level health state due to recurrent stroke, or die due to a recurrent stroke or a non-stroke cause (see Figure 1).

**Table 2. Outcomes and Efficacy of Patients Treated with tPA by Different Time From Onset to Needle.**

| Model Input | 0–1.5 hrs | 1.5–3 hrs | 3–4.5 hrs | Reference |
|-------------|-----------|-----------|-----------|-----------|
| **Percentage of patients** | | | | TIMS-CHINA database |
| **Functional outcome at 90 days after tPA treatment (%)** | | | | |
| No disability (mRS 0–1) | 5.68 | 61.13 | 33.19 | |
| Minor or moderate disability (mRS 2–3) | 53.97 | 47.11 | 48.09 | |
| Severe disability (mRS 4–5) | 23.81 | 24.89 | 25.14 | |
| Death (mRS 6) | 9.52 | 18.37 | 15.30 | |
| sICH (per ECASS II definition) | 12.70 | 9.63 | 11.47 | |
| **Odds ratio (95% CI) at day 90** | | | | |
| mRS 0–1 | 2.55 | 1.64 | 1.34 | 23 |
| (1.44–4.52) | (1.12–2.40) | (1.06–1.68) | 23 |
| Death | 0.78 | 1.13 | 1.22 | 23 |
| (0.41–1.48) | (0.70–1.82) | (0.87–1.71) | 23 |
| sICH | 8.23 | 8.23 | 3.61 | 23 |
| (2.39–28.32) | (2.39–28.32) | (1.76–7.38) | 23 |

**Table 2. Outcomes and Efficacy of Patients Treated with tPA by Different Time From Onset to Needle.**

| Model Input | 0–1.5 hrs | 1.5–3 hrs | 3–4.5 hrs | Reference |
|-------------|-----------|-----------|-----------|-----------|
| **Percentage of patients** | | | | TIMS-CHINA database |
| **Functional outcome at 90 days after tPA treatment (%)** | | | | |
| No disability (mRS 0–1) | 5.68 | 61.13 | 33.19 | |
| Minor or moderate disability (mRS 2–3) | 53.97 | 47.11 | 48.09 | |
| Severe disability (mRS 4–5) | 23.81 | 24.89 | 25.14 | |
| Death (mRS 6) | 9.52 | 18.37 | 15.30 | |
| sICH (per ECASS II definition) | 12.70 | 9.63 | 11.47 | |
| **Odds ratio (95% CI) at day 90** | | | | |
| mRS 0–1 | 2.55 | 1.64 | 1.34 | 23 |
| (1.44–4.52) | (1.12–2.40) | (1.06–1.68) | 23 |
| Death | 0.78 | 1.13 | 1.22 | 23 |
| (0.41–1.48) | (0.70–1.82) | (0.87–1.71) | 23 |
| sICH | 8.23 | 8.23 | 3.61 | 23 |
| (2.39–28.32) | (2.39–28.32) | (1.76–7.38) | 23 |

**tPA**, tissue plasminogen activator; mRS, modified Rankin Score; sICH, symptomatic intracerebral hemorrhage; ECASS II, Second European-Australasian Acute Stroke Study; TIMS-CHINA, Thrombolysis Implementation and Monitor of acute ischemic Stroke in China.

doi:10.1371/journal.pone.0110525.t002
Outcome Assessment

Health outcomes were measured in QALYs by multiplying years of life by utility scores derived from the literature. Utility estimates were based on published utility values stratified by mRS category [12,29,30]. Economic outcomes were measured in cumulative direct medical costs associated with stroke. The incremental cost-effectiveness ratio (ICER) was calculated by dividing the incremental costs by the incremental QALYs. We modeled outcomes and costs over the short-term (2 years) and the long-term (30 years). Using the willingness-to-pay threshold recommended by the Commission on Macroeconomics and Health of World Health Organization [31], the intervention was considered cost-effective if the ICER was less than CNY 105,000 (3x GDP per capita of China in 2011 [26], US$16,200) per QALY gained.

Sensitivity Analysis

The robustness of the model was tested by means of one-way sensitivity analyses for all variables across plausible ranges, which were obtained from the literature (Table 2, Table 3). To evaluate the impact of the parameter and stochastic uncertainty in all variables varied simultaneously, a probabilistic sensitivity analysis was performed using Monte Carlo simulation in Ersatz v1.3 (a bootstrap add-in for Microsoft Excel for Windows; EpiGear International Pty Ltd, Brisbane, Australia). We assumed the probabilities and utilities followed a beta distribution, and costs followed a lognormal distribution. The simulation was run 10,000 times to capture stability of the results. A scatter-plot and a cost-effectiveness acceptability curve were developed to represent uncertainty. Sensitivity analyses were only applied to the long-term (30 years) results.

Results

Base Case Analysis

Table 4 shows the outcomes, costs and ICER calculated in the short term (1, 2 years) and in the long term (30 years). In the base-case scenario, for a 63-year-old patient with acute ischemic stroke, tPA treatment would be cost-ineffective in the first year, but become cost-effective from the second year onwards, using the threshold of CNY 105,000 (3x GDP per capita of China in 2011, US$16,200) as the willingness-to-pay per QALY. After 2 years, tPA treatment gained 0.101 QALYs at an additional cost of CNY 9,520 (US$1,460), yielding an ICER of CNY 94,300 (US$16,200) per QALY gained. In the long term (30 years), tPA treatment gained 0.101 QALYs at an additional cost of CNY 15,500 (US$2,361) per QALY gained.

Sensitivity Analysis

One-way sensitivity analysis showed the results in the long term are robust. Tornado diagrams illustrated the effect of varying input parameters on the long term ICER (Figure 2). Overall, the ICER was most sensitive to odds ratio of favorable functional outcome at day 90 within 1.5–3 hours and annual post-hospitalization costs (mRS 2–5). If odds ratio of favorable functional outcome at day 90 within 1.5–3 hours increased to 2.40 from 1.12, the ICER of tPA treatment would drop to CNY 9,653/QALY from CNY 40,667/QALY. If annual post-hospitalization cost of disabling stroke (mRS 2–5) increased from CNY 2,380 to CNY 12,959, the ICER would decrease from CNY 37,014/QALY to CNY 8,057/QALY. In contrast, the ICER was relatively insensitive to odds ratio of sICH at day 90 and one-time hospitalization costs.

Discussion

Results of the probabilistic sensitivity analysis in the long term are shown in Figure 3. Among the 10,000 simulation runs, there was a 14.4% chance that tPA treatment turned to be less costly and more effective than non-tPA treatment. tPA treatment was cost-effective in 98.7% of the simulations at a willingness-to-pay threshold of CNY 105,000 (3x GDP per capita of China in 2011, US$16,200) per QALY, and still remained cost-effective in 79.2% of the simulations at a threshold of CNY 35,100 (1x GDP per capita of China in 2011, US$5,400) per QALY. The cost-effectiveness acceptability curve of tPA treatment is shown in Figure 4.

Our study indicated that tPA treatment for acute ischemic stroke within 4.5 hours was cost-effective not only in the short term (2 years), but also highly cost-effective in the long term (30 years) in China. A patient with acute ischemic stroke treated with tPA within 4.5 hours gain an ICER of CNY 15,500 per QALY, which was below 1x GDP per capita of China in 2011 (CNY 105,000). By contrast, cost effectiveness analyses conducted in some developed countries demonstrated tPA treatment was cost-saving in the long term [7–10]. We also found that the ICER is less sensitive to the additional costs of tPA treatment, but more sensitive to odds ratio of favorable functional outcome at day 90 within 1.5–3 hours and annual post-hospitalization costs (Figure 2). The reason might be that tPA treatment is highly effective in functional outcome for acute ischemic stroke (OR = 1.64 for 1.5–3 hours [23]), and also dramatically influence the long-term utility and costs, which may offset the costs of tPA treatment.

The differences between China and the developed countries may influence the cost-effectiveness of tPA treatment. First, unlike the diagnosis related payment system in most developed countries [18,19], China implements payment system according to the clinical services. The stroke-care related payments in China included medical care covered by government, medical insurance for urban workers, rural cooperative medical care, commercial medical insurance, plus patient own expense, in the proportions of 72%, 53.6%, 16.9%, 0.7% and 21.6%, respectively, according to CNSR (unpublished data). The out-of-pocket costs were only 10% to 20% of the total costs if the payment was covered by government. For urban workers with medical insurance, their average 3-month hospital and medication costs due to stroke were CNY 16,525 (US$2,361), while the out-of-pocket costs were CNY 14,478 (US$2,068) in 2006 [32]. However, for the patients without coverage from the government or medical insurance, they had to pay more out-of-pocket costs, with little support from state. No matter which payment resources that the stroke patients had, the total costs depended on the service and medicine prescribed, with huge variation in hospitals and geographical regions in China. In brief, Chinese patients must pay for all the costs first, and then search for corresponding reimbursement after the therapy process finished. For the patients without tPA treatment, their one-time hospitalization cost was CNY 9,526 if they had mRS 0–1, while if they had tPA treatment, the cost due to tPA alone was CNY 8,197 [US$1,261] in China [20]. Therefore, the cost of tPA in China were relatively higher than that in developed countries. Second, several surveys showed the lack of organized rehabilitation and decreased adherence to secondary prevention of ischemic stroke in China after discharge [33–36]. Therefore, the long-term post-hospitalization care costs might be similar between the tPA treatment group and the control group in China. Due to the facts above, clinically, it is very important to estimate the cost-
effectiveness in China. And these facts might partly explain the
difference in ICER between China and developed countries.

This study has several limitations. First, the costs used in the
model may not be accurate for each component of tPA related
treatments, tPA drugs, extra MRI scanning, extra consultant and
nursing services, change in length of stay, and so on [10].

However, we think the overall costs were recorded accurately in
the total hospitalization cost. We estimated the additional costs of
tPA treatment on the basis of the difference of the total
hospitalization costs of sICH-free patients with tPA treatment in
TIMS-CHINA study and the hospitalization costs of patients
without tPA treatment in CNSR. We calculated the additional

| Table 3. Base-case and the Range of Values Used in the Model. |
|--------------------------------------------------------------|
| **Model Input** | **Base Case** | **Range** | **Reference** |
| **Probabilities inputs** | | | |
| Recurrent rate of stroke (per patient year) | 0.1181 | 0.1123–0.1241 | CNSR |
| Relative risk of stroke recurrence per life year | 1.019 | 1.014–1.024 | CNSR |
| Death rate with recurrent stroke | 0.2101 | 0.1887–0.2316 | CNSR |
| Age specific non-stroke death rate* | 0.0089–0.1654 | 25,26 |
| Non-stroke death hazard ratios | 27 | | |
| mRS 0–1 | 1 | 1.0–1.2 | |
| mRS 2–3 | 1.19 | 1.1–1.3 | |
| mRS 4–5 | 2.04 | 1.4–3.0 | |
| **Cost inputs (2011 Chinese Yuan Renminbi)** | | | |
| Additional costs of tPA treatment | 10830 | 8385–12630 | CNSR, TIMS-CHINA |
| One-time hospitalization costs | | | |
| mRS 0–1 | 9526 | 5502–11994 | CNSR, 26 |
| mRS 2–5 | 12595 | 6922–16516 | |
| mRS 6 | 10794 | 5072–14267 | |
| Annual post-hospitalization costs | | | |
| mRS 0–1 | 6773 | 2028–8639 | CNSR |
| mRS 2–5 | 10305 | 2592–12959 | |
| **Utility inputs** | | | |
| No disability (mRS 0–1) | 0.80 | 0.80–0.95 | 12,29,30 |
| Minor or moderate disability (mRS 2–3) | 0.58 | 0.56–0.78 | |
| Severe disability (mRS 4–5) | 0.28 | 0.05–0.36 | |
| Death (mRS 6) | 0.00 | 0.00–0.00 | |
| **Discount rate inputs** | | | |
| Costs | 0.03 | 0.03–0.08 | 12 |
| Outcomes | 0.03 | 0.00–0.20 | 12 |

All costs were converted to 2011 Chinese Yuan Renminbi by using the medical care component of consumer price index; to convert CNY to US dollars, divide by 6.5.
tPA, tissue plasminogen activator; mRS, modified Rankin Score; sICH, symptomatic intracerebral hemorrhage; CNSR, China National Stroke Registry. TIMS-CHINA, Thrombolysis Implementation and Monitor of acute ischemic Stroke in China.

*Age specific non-stroke death rate: only the number of 63 years old (0.0089) and 93 years old (0.1654) are presented.

doi:10.1371/journal.pone.0110525.t003

| Table 4. Costs and Outcomes per Capita in Base-case Analysis. |
|---------------------------------------------------------------|
| **Time horizon** | **Treat strategy** | **QALYs** | **Cost (CNY)** | **ICER (CNY/QALY)** |
| 1 year | No tPA | 0.655 | 20,680 | - |
| | tPA | 0.711 | 30,850 | 181,607 |
| 2 years | No tPA | 1.102 | 29,460 | - |
| | tPA | 1.203 | 38,980 | 94,257 |
| 30 years | No tPA | 4.571 | 114,350 | - |
| | tPA | 4.993 | 120,880 | 15,474 |

tPA, tissue plasminogen activator; QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio.
doi:10.1371/journal.pone.0110525.t004
Figure 2. One-way sensitivity analyses on incremental cost-effectiveness ratio (ICER) gained in the long term (30 years) by tPA treatment within 4.5 hours. All model parameters were analyzed, and only those with the highest relative effect on ICER are displayed. Dark shaded bars represent the lower bound, while light shaded bars represent the upper bound of the parameter range. Base-case scenario of ICER is CNY 15,500 per quality-adjusted life-year (QALY) gained.

doi:10.1371/journal.pone.0110525.g002

Figure 3. Scatterplot of the result of probabilistic sensitivity analysis comparing tPA treatment within 4.5 hours with no tPA treatment. Each point represents a simulation. The dark square represents the base case (0.422 QALYs gained at an incremental cost of CNY 6,530). The solid line represents the willingness-to-pay threshold of CNY 105,000 per QALY. The dashed line represents CNY 35,100 per QALY. Points to the right of the willingness-to-pay line are considered cost-effective.

doi:10.1371/journal.pone.0110525.g003
costs of sICH applying the same rationale. Second, in China, the family plays an important role in both acute and post-acute care. This informal caregiving can be quite expensive. However, it was not considered in our model because of lack of corresponding data. Third, our model focused on the influence of tPA for acute ischemic stroke, and functional status and costs as a result of other causes, such as recurrence of intracranial hemorrhage, myocardial infarction, congestive heart failure, were not included in this model. In addition, the improved functional status after rehabilitation or other improvements was not considered in the model for lack of organized rehabilitation in China and lack of authentic data available on efficacy of rehabilitation or other improvements. Fourth, the efficacy of tPA treatment was based on the pooled analyses from the studies in developed countries (ECASS, ATLANTIS, NINDS, and EPITHET). Also, the utilities references were from Western literatures. We applied the efficacy of tPA treatment and the utilities to the model of Chinese patients, but did not know if these data fit Chinese patients. However, we ran sensitivity analysis and found that the results were robust for these parameters across plausible ranges. Although these limitations would have led to under- or over-estimation of the true cost-effectiveness of tPA treatment in China, it is unlikely to make a significant differential impact on the overall results of our study because our findings were robust as shown in the sensitivity analyses.

Conclusions

The intravenous tPA within 4.5 hours for patients with acute ischemic stroke is highly cost-effective in China. Our study provides with constructive information on medical resource allocation for stroke treatment in China in future, and may also be a reference to other developing countries.

Figure 4. Cost-effectiveness acceptability curve. The curve presents the probability that tPA treatment within 4.5 hours to be cost-effective against willingness-to-pay threshold. The solid line represents the willingness-to-pay threshold of CNY 105,000 per QALY. The dashed line represents CNY 35,100 per QALY. doi:10.1371/journal.pone.0110525.g004

Acknowledgments

Special thanks to the physicians as well as all other personnel who dedicated themselves to the TIMS-CHINA project. The TIMS-CHINA investigators include: Yongjun Wang (Principle investigator, E-mail: ; yongjunwang1962@gmail.com), Beijing Tiantan Hospital; Xingquan Zhao, Beijing Tiantan Hospital; Yulong Wang, Beijing Tiantan Hospital; Xiaoling Liao, Beijing Tiantan Hospital; Chunxue Wang, Beijing Tiantan Hospital; Liping Liu, Beijing Tiantan Hospital; Chunjuan Wang, Beijing Tiantan Hospital; Yuesong Pan, Beijing Tiantan Hospital; Qi Bi, Beijing Anzhen Hospital; Liying Cui, Peking Union Medical College Hospital of Peking University; Yuheng Sun, Beijing Jishuitan Hospital; Maolin He, Beijing Shijitan Hospital; Dongsheng Fan, Peking University Third Hospital; Xiaojuan Zhang, Beijing Tongren Hospital; Yansheng Li, Shanghai Renji Hospital; Shaoqin Wang, Shanghai First Municipal People’s Branch hospital; Wei Fan, Zhongshan Hospital of Fudan University; Chuancheng Ren, The Fifth People’s Hospital of Shanghai; Fudan University; Zhenguo Liu, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University; Xiaojiang Sun, The sixth People’s Hospital Affiliated to Shanghai Jiao Tong University; Xu Chen, Shanghai 8th People’s Hospital; Qingke Bai, Pudong New Area People’s Hospital; Daxiang Gu, Shanghai Yangpu Area Shidong hospital; Qiang Dong, Huashan Hospital of Fudan University; Yan Cheng, Tianjin Medical University Gengda Hospital; Xie Song, Dagang Oilfield Gengda Hospital; Chen Li,Tianjin Fifth Center Hospital; Tongyu Wang, Bohai Oilfield Hospital; Liping Wang,Ninghe County People’s Hospital of Tianjin; Kun Zhao, Baodi District People’s Hospital of Tianjin; Dingbo Tao, The First Affiliated Hospital of Dalian Medical University; Fang Qu, Dalian Second People’s hospital; Jingbo Zhang, Dalian Third People’s hospital; Jianfeng Wang, Dalian Central hospital; Ying Lian, Dalian Economic and Technological Development District Hospital; Fang Qu, Shenyang Military District General hospital of Chinese People’s Liberation Army; Ying Gao, National Traditional Chinese Medicine (TCM) Thrombus Treatment Center of Liaoning Province; Huashan Sun, Jilin Chemical Industrial Group General hospital; Jinying Li, Jilin Oilfield General Hospital; Guozhong Li, The First Clinical College of Harbin Medical University; Yulan Zhu, The Second Clinical College of Harbin Medical University; Zichao Yang, The Fourth Clinical College of Harbin
Medical University; Jun Zhou, Mudan Jiang Second hospital; Minxia Guo, Shanaexi Provincial People’s Hospital; Qilin Ma, The First Hospital of Xiamen; Xiaopiao Gao, Hunan Provincial People’s Hospital; Reabin Huang, Chenzhou First People’s Hospital; Bo Xiao, Xiangya Hospital of Centre-south university; Kangning Chen, Southwest Hospital; Li Gao, Chengdu Third Municipal People’s Hospital; Anding Xu, The First Affiliated Hospital of Jinan University; Ming Shao, The First Affiliated Hospital of Guangzhou Medical University; En Guo, The Second Affiliated Hospital of Guangzhou Medical University; Xiaoping Pan, Guangzhou First Municipal People’s Hospital; Yefeng Cai, Guangdong Provincial Hospital of Traditional Chinese Medicine; Yun Xu, Drum Tower Hospital Affiliated to Nanjing Medical University; Kailu Ke, The Affiliated Hospital of Nantong University; Yuenan Kong, Wuxi Second People’s Hospital; Liangcai Ding, The Third Affiliated Hospital of Suzhou University; Yi Lin, Huang, Chenzhou First People’s Hospital; Kang Xu, HuBei Xinhua Hospital; Chengming Xing, Qingdao Municipal Hospital Group; Shacha Su, Dezhou People’s Hospital; Guirui Zhang, Penglai People’s Hospital; Rongyuan Zheng, The First Affiliated Hospital of Wenzhou Medical University; Ming Zhai, First People’s Hospital of Yunnan Province; Yi Zhu, The Xinjiang Autonomous Region People’s Hospital; Yuanyin Liu, Autonomous Region TCM Hospital Affiliated to Xinjiang Medical University; Xiaoying Zhang, Hospital of Xinjiang Production & Construction Corps; Zhizheng Wu, Qinghai Provincial People’s Hospital; Jinfeng Liu, Yangquan Coalmine Group General hospital. In addition, we thank Dr. Jiming Fang for helpful edits on the manuscript.

Author Contributions

Conceived and designed the experiments: YSP Yilong Wang Yongjun Wang. Performed the experiments: QDG NQZ XLL Chunjiang Wang. Analyzed the data: YSP GFL Wang. Contributed reagents/materials/analysis tools: NQZ WLD LPL. Wrote the paper: YSP Chuxue Wang Yilong Wang Yongjun Wang.

References

1. Yang G, Wang Y, Zeng Y, Gao GF, Liang X, et al. (2013) Rapid health transition in China 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet 381: 1987–2015.
2. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, et al. (1995) Intraoperative thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 274: 1017–1025.
3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1993) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333: 1501–1507.
4. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, et al. (2004) Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363: 768–774.
5. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, et al. (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute stroke: N Engl J Med 359: 1317–1329.
6. Wahlgren N, Ahmed N, Davalos A, Hacke W, Mårtensson H, et al. (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute stroke. N Engl J Med 359: 1301–1316.
7. Fagan SC, Morgenstern LR, Pettit A, Ward RE, Talley RC, et al. (1998) Cost-effectiveness of tissue plasminogen activator for acute stroke. NINDS rt-PA Stroke Study Group. Neurology 50: 833–839.
8. Sinclair SE, Frihjertoft L, Loewen PS, Sunderji R, Teal P, et al. (2001) Cost-Utility analysis of tissue plasminogen activator therapy for acute ischemic stroke: a Canadian healthcare perspective. Pharmacoeconomics 19: 927–936.
9. Sandercock P, Berge E, Dennis M, Forbes J, Hand P, et al. (2004) Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischaemic stroke assessed by a model based on UK NHS costs. Stroke 35: 1490–1497.
10. Ehlers I, Anderson G, Chauvin LB, Behm C, Kjelby M (2007) Cost-effectiveness of intraoperative thrombolysis with alteplase within a 3-hour window after acute ischemic stroke. Stroke 38: 85–89.
11. Jung KT, Shin DW, Lee KJ, Oh M (2010) Cost-effectiveness of recombinant tissue plasminogen activator in the management of acute ischemic stroke: a systematic review. J Clin Neurol 6: 117–126.
12. Tung CF, Win SS, Lamsberg MG (2011) Cost-effectiveness of tissue-type plasminogen activator in the 3- to 4.5-hour time window for acute ischemic stroke. Stroke 42: 2257–2262.
13. Kim AS, Nguyen-Huyh M, Johnston SC (2011) A cost-utility analysis of mechanical thrombectomy as an adjunct to intraoperative tissue plasminogen activator for acute large-vessel ischemic stroke. Stroke 42: 2013–2018.
14. Boultraud DM, Guzuszak G, Villa KF, Fagan SC, Veerstra DL (2012) A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Ann Emerg Med 61: 46–55.
15. Tan Tanny SP, Buja I, Liew D, Too S, Davis SM, et al. (2013) Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke experience from Australian stroke centre. Stroke 44: 2269–2274.
16. Kim AS, Johnston SC (2013) Temporal and geographic trends in the global stroke epidemic. Stroke 44: S123–S125.
17. Wang Y, Liao X, Zhao X, Wang DF, Wang C, et al. (2011) Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR). Stroke 42: 1658–1664.
18. DeMaerschalk BM, Durocher DL (2007) How diagnosis-related group 559 will change the US Medicare cost reimbursement ratio for stroke centers. Stroke 38: 1309–1312.